| 2015-GHOS-67161 | |
| HIV/AIDS is one of the top deadly diseases worldwide that is still common despite progress in healthcare. Human immunodeficiency virus (HIV) causes acquired immune deficiency syndrome (AIDS), which is a complex disease that includes gradual destruction of the immune system. Many current therapies that are available for the management of the disease are limited by their duration of action, side effect profile and toxicity, and their extensive pill burden. Hence, there is a need to find newer therapies for HIV/AIDS. Researchers at Purdue University have developed a series of non-peptide HIV-1 protease inhibitors that incorporate a basic amine function in the inhibitor structure. These compounds are novel and show enzyme inhibition and antiviral activity at subnanomolar levels. In addition, they have been shown to have potent activity against multidrug resistant HIV-1 strains and are expected to have improved metabolic stability and pharmacokinetic properties. These compounds have potential use in the pharmaceutical industry for the development of superior HIV medications and in healthcare for the treatment of HIV/AIDS. Advantages: -HIV-1 protease inhibitor -Potent activity against resistant strains -Improved stability and pharmacokinetics Potential Applications: -Pharmaceutical industry -Drug development -Medical/Healthcare -Treatment of HIV/AIDS |
|
|
|
|
Aug 17, 2016
NATL-Patent
European Patent
3337567
Oct 6, 2021
Feb 17, 2018
NATL-Patent
United States
10,472,372
Nov 12, 2019
Oct 10, 2019
CON-Patent
United States
(None)
(None)
Aug 17, 2016
PCT-Patent
WO
(None)
(None)
Aug 17, 2016
NATL-Patent
Japan
(None)
(None)
Aug 17, 2015
Provisional-Patent
United States
(None)
(None)
|
|
|
Purdue Office of Technology Commercialization The Convergence Center 101 Foundry Drive, Suite 2500 West Lafayette, IN 47906 Phone: (765) 588-3475 Fax: (765) 463-3486 Email: otcip@prf.org |
